A Randomized Open Label Study of Brigatinib vs Alectinib in Advanced Anaplastic Lymphoma Kinase Positive Non Small Cell Lung Cancer Patients Who Have Progressed on Crizotinib (18129) (Brigatinib-3001)

A Randomized Open Label Study of Brigatinib vs Alectinib in Advanced Anaplastic Lymphoma Kinase Positive Non Small Cell Lung Cancer Patients Who Have Progressed on Crizotinib (18129) (Brigatinib-3001)

Trial Category:
Lung
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE

This study will evaluate two new drugs for a specific group of lung cancer patients who have had the tumor progress while using the drug Crizotinib.  Patients are "randomized" on this study.  This means a computer tells the study team which treatment you will receive.  Neither the patient or the physician can choose the treatment assignment.  The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment. 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members